CORAL GABLES, FL / ACCESSWIRE / July 6, 2016 / / Daily Stock Reporter is issuing a report on four stocks to watch. Galena Biopharma, Inc. (NASDAQ: GALE), Birks Group Inc. (NYSE MKT: BGI), LifeClips Inc. (OTCQB: LCLP), andArch Therapeutics (OTCQB: ARTH) have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.

Galena Biopharma, Inc. (NASDAQ: GALE) has made headlines over the last few weeks and most notably announcing that its PRESENT trial will be stopped due to futility. "We are extremely disappointed with the outcome of the PRESENT futility analysis," said Mark W. Schwartz, Ph.D., President and Chief Executive Officer. "On behalf of our entire company, I would like to thank all of the courageous patients and their families, investigators, study staff and independent committees who participated in the PRESENT study."

According to the company, the trial has not been un-blinded other than by the IDMC, and management needs to evaluate the data. "We expect to host a conference call next week to provide a preliminary review of the PRESENT trial and an update on all of our immunotherapy and hematology clinical development programs."

Shares of GALE tumbled to lows of $0.275 but have since recovered in a major way after hitting highs on Tuesday of $0.7737. This has marked a total turn around in price by as much as 181% in just a few days. Get More Information on GALE, Here.

Stay Informed and Up To Date On The Hottest Small Cap Nasdaq & OTC Plays. Get Them Here.

Birks Group Inc. (NYSE MKT: BGI) has captivated traders this week as shares have seen explosive movement in price and volume. Since opening the week at $0.60, shares of BGI have moved up as high as $5.15 to mark a run of as much as 758%. The Montreal company announced on Tuesday that the Company improved its net income for the year by $14.0 million over last year, from a net loss of $8.6 million last year to a net income of $5.4 million this year. They also showed comparable store sales increased by 3% even in a "challenging retail environment."

Birks operates 46 luxury jewelry stores in Canada , Florida and Georgia. The company highlights strict cost controls and rigorous cash management as two of the most prominent contributors to its recent success. Enjoy Trades Like BGI? Click For More Info.

Enjoy picks like this? Get These Alerts and More on top small cap Companies before They Rally, Text the phrase "StockAlerts" to 82257

LifeClips Inc. (OTCQB: LCLP) has made some of its biggest updates within the last few weeks. LCLP revealed the company's current list of retailers included for the soft launch of its Mobeego® single use charging device. Outlets include B & H Photo Video in New York City as well as several outlets in MGM properties in Las Vegas, NV. "Welcome to the U.S.A Mobeego®!," said CEO Bob Gruder. "I would like to thank our shareholders, distributors & our entire team for making this possible. Mobeego® is a revenue producing, recognizable brand in 14 different countries & it's time the United States gets its fair share of the pie."

This was followed up last week with an announcement that the company signed an exclusive distribution agreement with Cities Market for action camera distribution into BestBuy, Target, and inclusion within their respective online retail "storefronts." On top of this, the company announced this morning that it would also be developing a new line of 360-degree action cameras to be scheduled for release in August of 2016.

The activity brought from company announcements has helped to propel the stock from trading between $0.40 and $0.50 to recent highs of $0.70. Today's announcement could be the first step in opening an entirely new line of products for the company has 360-degree cameras have begun to gain much more popularity on outlets like social media and news sites. You Can View LCLP's News Here.

Stay Informed and Up To Date On The Hottest Small Cap Stocks; Free To Join Now.

Arch Therapeutics (OTCQB: ARTH) announced at the beginning of June that it had completed its patient enrollment in the clinical study of its AC5 Hemostatic Device. The company has focused the device on the control of bleeding and fluid loss in order to provide quick and safe surgical care. The study has been designed to test the performance and safety in humans and is being done in collaboration with CÚRAM, Science Foundation Ireland Centre for Research in Medical Devices and the Clinical Research Facility based at National University of Ireland Galway.

Since making the announcement, the company's stock price has skyrocketed from $0.41 to as high as $0.68 on Tuesday. With the company anticipating to report follow-up assessment of the 46 patient study within "30 days," the time is getting closer to that next piece of information with today being 30 days since the June 6 announcement. Will ARTH Move Higher? Click Here.

Small Cap Stock Alerts: Get Them straight to your Cell Phone. To Receive Our Winning Small Cap Stock Alerts For Free, text "StockAlerts" to 82257.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase "StockAlerts" to 82257.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. A full disclaimer can be found at www.DailyStockReporter.com/disclaimer.

EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.

EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: DailyStockReporter.com
Contact Email: news@dailystockreporter.com

SOURCE: DailyStockReporter.com